Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MMP13 | P45452 | 3/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.44 |
| ▸ | TUBB | P07437 | 2/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568231 | 0.90 | SMN1; SMN2 (0.49) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4568445 | 0.85 | TUBB4A (0.44) | MAPTNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL4568514 | 0.85 | MMP13 (0.47) | MAPTNPC1RAB9AHSP90AA1SMN1; SMN2 | |
| SCHEMBL15975191 | 0.84 | SMN1; SMN2 (0.49) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3715217 | 0.81 | MAPT (0.43) | MAPTNPC1RAB9AHSP90AA1SMN1; SMN2 | |
| SCHEMBL4568562 | 0.78 | TUBB4A (0.48) | SMN1; SMN2ALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL15998612 | 0.78 | ALDH1A1 (0.42) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4568446 | 0.78 | TUBB4A (0.46) | MAPTALDH1A1LMNATUBB4ATUBB | |
| SCHEMBL3698700 | 0.77 | TUBB4A (0.44) | MAPTNPC1RAB9AHSP90AA1SMN1; SMN2 | |
| SCHEMBL4568441 | 0.76 | TUBB4A (0.46) | MAPTRAB9ASMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8815903-B2 | Indole derivative and pharmacologically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| EP-2669272-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT OF SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20130317065-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL COMPANY, LIMITED (JP) | 2013-11-28 | — | — | US | disclosed |
| EP-2474530-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | MAPT 3199/4885NPC1 1150/4885RAB9A 1646/4885 |
| US-20130317065-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | MAPT 3362/4885NPC1 1715/4885RAB9A 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.